Back to All
Group

Webinar: Which Pharma Companies Are Dx Ready For Precision Medicine in 2017? Benchmarking, Financial Risks and Predictions

20 December, 2016

For the 2017 Pharma Readiness for Dx Index, Diaceutics applies analyses to 23 companies and examines the precision medicine (PM) credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy (Rx) assets. We include Big Data and lab partnerships alongside Rx/Dx partnerships to reflect the evolution of PM beyond molecular testing? and make considered predictions for the industry as it develops. Listen to the webinar to learn:

  • What's new in this year’s Pharma Readiness for Dx report
  • How the diagnostic market is currently placed and where it is heading in 2017 and beyond
  • How pharma readiness and financial risks can impact the industry

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny